Mechanisms of hepatocyte growth factor activation in cancer tissues

Cancers

Volumn 6, Issue 4, 2014, Pages 1890-1904

  Kawaguchi, Makiko ^a   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

HAI 1; HAI 2; Hepatocyte growth factor; Hepatocyte growth factor activator; Matriptase; TTSP

Indexed keywords

HEPATOCYTE GROWTH FACTOR ACTIVATOR; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 2; HEPSIN; KALLIKREIN; KALLIKREIN 4; KALLIKREIN 5; MATRIPTASE; PROTEINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSMEMBRANE SERINE PROTEASE 13; TRYPTASE; UNCLASSIFIED DRUG; UROKINASE;

CANCER CELL LINE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL SURFACE; CELLULAR DISTRIBUTION; ENZYME ACTIVATION; ENZYME REGULATION; EPIGENETICS; GENE SILENCING; HUMAN; LIVER; MALIGNANT TRANSFORMATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT;

EID: 84907615350     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6041890     Document Type: Review

References (101)

1. Hanahan, D.; Coussens, L.M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21, 309–322.
2. Matsumoto, K.; Nakamura, T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer 2006, 119, 477–483.
3. Trusolino, L.; Bertotti, A.; Comoglio, P.M. MET signalling: Principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2010, 11, 834–848.
4. Koeppen, H.; Rost, S.; Yauch, R.L. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors. J. Pathol. 2014, 232, 210–218.
5. Gak, E.; Taylor, W.G.; Chan, A.M.; Rubin, J.S. Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. FEBS Lett. 1992, 311, 17–21.
6. Hartmann, G.; Naldini, L.; Weidner, K.M.; Sachs, M.; Vigna, E.; Comoglio, P.M.; Birchmeier, W. A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc. Natl. Acad. Sci. USA 1992, 89, 11574–11578.
7. Naka, D.; Ishii, T.; Yoshiyama, Y.; Miyazawa, K.; Hara, H.; Hishida, T.; Kidamura, N. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J. Biol. Chem. 1992, 267, 20114–20119.
8. Naldini, L.; Tamagnone, L.; Vigna, E.; Sachs, M.; Hartmann, G.; Birchmeier, W.; Daikuhara, Y.; Tsubouchi, H.; Blasi, F.; Comoglio, P.M.; et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992, 11, 4825–4833.
9. Kirchhofer, D.; Yao, X.; Peek, M.; Eigenbrot, C.; Lipari, M.T.; Billeci, K.L.; Maun, H.R.; Moran, P.; Santell, L.; Wiesmann, C.; et al. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling. J. Biol. Chem. 2004, 279, 39915–39924.
10. Lokker, N.A.; Mark, M.R.; Luis, E.A.; Bennett, G.L.; Robbins, K.A.; Baker, J.B.; Godowski, P.J. Structure-function analysis of hepatocyte growth factor: Identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 1992, 11, 2503–2510.
11. Kataoka, H.; Miyata, S.; Uchinokura, S.; Itoh, H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev. 2003, 22, 223–236.
12. Nakamura, T.; Sakai, K.; Nakamura, T.; Matsumoto, K. Hepatocyte growth factor twenty years on: Much more than a growth factor. J. Gastroenterol. Hepatol. 2011, 26, 188–202.
13. Kataoka, H.; Kawaguchi, M. Hepatocyte growth factor activator (HGFA): Pathophysiological functions in vivo. FEBS J. 2010, 277, 2230–2237.
14. Owen, K.A.; Qiu, D.; Alves, J.; Schumacher, A.M.; Kilpatrick, L.M.; Li, J.; Harris, J.L.; Ellis, V. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem. J. 2010, 426, 219–228.
15. Nakamura, T.; Matsumoto, K.; Kiritoshi, A.; Tano, Y. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions. Cancer Res. 1997, 57, 3305–3313.
16. Xie, Q.; Bradley, R.; Kang, L.; Koeman, J.; Ascierto, M.L.; Worschech, A.; de Giorgi, V.; Wang, E.; Kefene, L.; Su, Y.; et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc. Natl. Acad. Sci. USA 2012, 109, 570–575.
17. Miyazawa, K.; Shimomura, T.; Naka, D.; Kitamura, N. Proteolytic activation of hepatocyte growth factor in response to tissue injury. J. Biol. Chem. 1994, 269, 8966–8970.
18. Kataoka, H.; Hamasuna, R.; Itoh, H.; Kitamura, N.; Koono, M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res. 2000, 60, 6148–6159.
19. Hoshiko, S.; Kawaguchi, M.; Fukushima, T.; Haruyama, Y.; Yorita, K.; Tanaka, H.; Seiki, M.; Inatsu, H.; Kitamura, K.; Kataoka, H.; et al. Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. Cancer Res. 2013, 73, 2659–2670.
20. Olivero, M.; Rizzo, M.; Madeddu, R.; Casadio, C.; Pennacchietti, S.; Nicotra, M.; Prat, M.; Maggi, G.; Arena, N.; Natali, P.; et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br. J. Cancer 1996, 74, 1862–1868.
21. Yamauchi, M.; Kataoka, H.; Itoh, H.; Seguchi, T.; Hasui, Y.; Osada, Y. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J. Urol. 2004, 171, 890–896.
22. Kitajima, Y.; Ide, T.; Ohtsuka, T.; Miyazaki, K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 2008, 99, 1341–1347.
23. Peek, M.; Moran, P.; Mendoza, N.; Wickramasinghe, D.; Kirchhofer, D. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J. Biol. Chem. 2002, 277, 47804–47809.
24. Kirchhofer, D.; Peek, M.; Lipari, M.T.; Billeci, K.; Fan, B.; Moran, P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 2005, 579, 1945–1950.
25. Hashimoto, T.; Kato, M.; Shimomura, T.; Kitamura, N. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. FEBS J. 2010, 277, 4888–4900.
26. Kato, M.; Hashimoto, T.; Shimomura, T.; Kataoka, H.; Ohi, H.; Kitamura, N. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease. J. Biochem. 2012, 151, 179–187.
27. Mars, W.M.; Zarnegar, R.; Michalopoulos, G.K. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am. J. Pathol. 1993, 143, 949–958.
28. Naldini, L.; Vigna, E.; Bardelli, A.; Follenzi, A.; Galimi, F.; Comoglio, P.M. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J. Biol. Chem. 1995, 270, 603–611.
29. Kawaguchi, M.; Orikawa, H.; Baba, T.; Fukushima, T.; Kataoka, H. Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein. FEBS J. 2009, 276, 3481–3490.
30. Dvorak, H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650–1659.
31. Nierodzik, M.L.; Karpatkin, S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006, 10, 355–362.
32. Mukai, S.; Fukushima, T.; Naka, D.; Tanaka, H.; Osada, Y.; Kataoka, H. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. FEBS J. 2008, 275, 1003–1017.
33. Moriyama, T.; Kataoka, H.; Tsubouchi, H.; Koono, M. Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro. FEBS Lett. 1995, 372, 78–82.
34. Parr, C.; Jiang, W.G. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int. J. Oncol. 2001, 19, 857–863.
35. Tjin, E.P.M.; Groen, R.W.J.; Vogelzang, I.; Derksen, P.W.B.; Klok, M.D.; Meijer, H.P.; van Eeden, S.; Pals, S.T.; Spaargaren, M. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006, 107, 760–768.
36. Tjin, E.P.M.; Derksen, P.W.B.; Kataoka, H.; Spaargaren, M.; Pals, S.T. Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 2004, 104, 2172–2175.
37. Wader, K.F.; Fagerli, U.M.; Holt, R.U.; Stordal, B.; Børset, M.; Sundan, A.; Waage, A. Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. Eur. J. Haematol. 2008, 81, 380–383.
38. Nagakawa, O.; Yamagishi, T.; Fujiuchi, Y.; Junicho, A.; Akashi, T.; Nagaike, K.; Fuse, H. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur. Urol. 2005, 48, 686–690.
39. Parr, C.; Watkins, G.; Mansel, R.E.; Jiang, W.G. The hepatocyte growth factor regulatory factors in human breast cancer. Clin. Cancer Res. 2004, 10, 202–211.
40. Lin, C.Y.; Wang, J.K.; Torri, J.; Dou, L.; Sang, Q.A.; Dickson, R.B. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J. Biol. Chem. 1997, 272, 9147–9152.
41. Takeuchi, T.; Shuman, M.A.; Craik, C.S. Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA 1999, 96, 11054–11061.
42. Oberst, M.D.; Singh, B.; Ozdemirli, M.; Dickson, R.B.; Johnson, M.D.; Lin, C.-Y. Characterization of matriptase expression in normal human tissues. J. Histochem. Cytochem. 2003, 51, 1017–1025.
43. List, K.; Szabo, R.; Molinolo, A.; Nielsen, B.S.; Bugge, T.H. Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am. J. Pathol. 2006, 168, 1513–1525.
44. List, K.; Bugge, T.H.; Szabo, R. Matriptase: Potent proteolysis on the cell surface. Mol. Med. 2006, 12, 1–7.
45. Inouye, K.; Yasumoto, M.; Tsuzuki, S.; Mochida, S.; Fushiki, T. The optimal activity of a pseudozymogen form of recombinant matriptase under the mildly acidic pH and low ionic strength conditions. J. Biochem. 2010, 147, 485–492.
46. Wang, J.-K.; Teng, I.-J.; Lo, T.-J.; Moore, S.; Yeo, Y.H.; Teng, Y.-C.; Kaul, M.; Chen, C.-C.; Zuo, A.H.; Chou, F.-P.; et al. Matriptase autoactivation is tightly regulated by the cellular chemical environments. PLoS One 2014, 9, e93899.
47. Tannock, I.F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989, 49, 4373–4384.
48. Antalis, T.M.; Buzza, M.S.; Hodge, K.M.; Hooper, J.D.; Netzel-Arnett, S. The cutting edge: Membrane-anchored serine protease activities in the pericellular microenvironment. Biochem. J. 2010, 428, 325–346.
49. Oberst, M.D.; Johnson, M.D.; Dickson, R.B.; Lin, C.-Y.; Singh, B.; Stewart, M.; Williams, A.; al-Nafussi, A.; Smyth, J.F.; Gabra, H.; et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: Correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res. 2002, 8, 1101–1107.
50. Kang, J.Y.; Dolled-Filhart, M.; Ocal, I.T.; Singh, B.; Lin, C.-Y.; Dickson, R.B.; Rimm, D.L.; Camp, R.L. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 2003, 63, 1101–1105.
51. Jarzab, B.; Wiench, M.; Fujarewicz, K.; Simek, K.; Jarzab, M.; Oczko-Wojciechowska, M.; Wloch, J.; Czarniecka, A.; Chmielik, E.; Lange, D.; et al. Gene expression profile of papillary thyroid cancer: Sources of variability and diagnostic implications. Cancer Res. 2005, 65, 1587–1597.
52. Lee, J.-W.; Yong Song, S.; Choi, J.-J.; Lee, S.-J.; Kim, B.-G.; Park, C.-S.; Lee, J.-H.; Lin, C.-Y.; Dickson, R.B.; Bae, D.-S.; et al. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum. Pathol. 2005, 36, 626–633.
53. Saleem, M.; Adhami, V.M.; Zhong, W.; Longley, B.J.; Lin, C.-Y.; Dickson, R.B.; Reagan-Shaw, S.; Jarrard, D.F.; Mukhtar, H. A novel biomarker for staging human prostate adenocarcinoma: Overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol. Biomark. Prev. 2006, 15, 217–227.
54. Nakamura, K.; Hongo, A.; Kodama, J.; Abarzua, F.; Nasu, Y.; Kumon, H.; Hiramatsu, Y. Expression of matriptase and clinical outcome of human endometrial cancer. Anticancer Res. 2009, 29, 1685–1690.
55. Ha, S.Y.; Kim, K.Y.; Lee, N.K.; Kim, M.G.; Kim, S.-H. Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma. Virchows Arch. 2014, 464, 19–27.
56. Cheng, M.-F.; Huang, M.-S.; Lin, C.-S.; Lin, L.-H.; Lee, H.-S.; Jiang, J.-C.; Hsia, K.-T. Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma. Histopathology 2014, 65, 24–34.
57. Chou, F.-P.; Chen, Y.-W.; Zhao, X.F.; Xu-Monette, Z.Y.; Young, K.H.; Gartenhaus, R.B.; Wang, J.-K.; Kataoka, H.; Zuo, A.H.; Barndt, R.J.; et al. Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas. Am. J. Pathol. 2013, 183, 1306–1317.
58. List, K.; Szabo, R.; Molinolo, A.; Sriuranpong, V.; Redeye, V.; Murdock, T.; Burke, B.; Nielsen, B.S.; Gutkind, J.S.; Bugge, T.H.; et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 2005, 19, 1934–1950.
59. Szabo, R.; Rasmussen, A.L.; Moyer, A.B.; Kosa, P.; Schafer, J.M.; Molinolo, A.A.; Gutkind, J.S.; Bugge, T.H. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene 2011, 30, 2003–2016.
60. Kosa, P.; Szabo, R.; Molinolo, A.A.; Bugge, T.H. Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. Oncogene 2012, 31, 3679–3695.
61. Zhang, Y.; Cai, X.; Schlegelberger, B.; Zheng, S. Assignment1 of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24→q25 by in situ hybridization. Cytogenet. Cell Genet. 1998, 83, 56–57.
62. Shimomura, T.; Denda, K.; Kitamura, A.; Kawaguchi, T.; Kito, M.; Kondo, J.; Kagaya, S.; Qin, L.; Takata, H.; Miyazawa, K.; et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J. Biol. Chem. 1997, 272, 6370–6376.
63. Kawaguchi, T.; Qin, L.; Shimomura, T.; Kondo, J.; Matsumoto, K.; Denda, K.; Kitamura, N. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J. Biol. Chem. 1997, 272, 27558–27564.
64. Marlor, C.W.; Delaria, K.A.; Davis, G.; Muller, D.K.; Greve, J.M.; Tamburini, P.P. Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. J. Biol. Chem. 1997, 272, 12202–12208.
65. Denda, K.; Shimomura, T.; Kawaguchi, T.; Miyazawa, K.; Kitamura, N. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J. Biol. Chem. 2002, 277, 14053–14059.
66. Itoh, H.; Kataoka, H.; Hamasuna, R.; Kitamura, N.; Koono, M. Hepatocyte growth factor activator inhibitor type 2 lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human. Biochem. Biophys. Res. Commun. 1999, 255, 740–748.
67. Qin, L.; Denda, K.; Shimomura, T.; Kawaguchi, T.; Kitamura, N. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 2. FEBS Lett. 1998, 436, 111–114.
68. Kataoka, H.; Itoh, H.; Nuki, Y.; Hamasuna, R.; Naganuma, S.; Kitamura, N.; Shimomura, T. Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator. Biochem. Biophys. Res. Commun. 2002, 290, 1096–1100.
69. Kataoka, H.; Suganuma, T.; Shimomura, T.; Itoh, H.; Kitamura, N.; Nabeshima, K.; Koono, M. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J. Histochem. Cytochem. 1999, 47, 673–682.
70. Szabo, R.; Hobson, J.P.; List, K.; Molinolo, A.; Lin, C.-Y.; Bugge, T.H. Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J. Biol. Chem. 2008, 283, 29495–29504.
71. Zeng, L.; Cao, J.; Zhang, X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J. Gastroenterol. 2005, 11, 6202–6207.
72. Nakamura, K.; Abarzua, F.; Kodama, J.; Hongo, A.; Nasu, Y.; Kumon, H.; Hiramatsu, Y. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. Int. J. Oncol. 2009, 34, 345–353.
73. Nakamura, K.; Hongo, A.; Kodama, J.; Hiramatsu, Y. The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Int. J. Cancer 2011, 128, 2613–2624.
74. Vogel, L.K.; Saebø, M.; Skjelbred, C.F.; Abell, K.; Pedersen, E.D.K.; Vogel, U.; Kure, E.H. The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer 2006, doi:10.1186/1471-2407-6-176.
75. Ye, J.; Cheng, H.; Wang, Y.; Cao, J. Down-regulation of HAI-1 is associated with poor-differentiation status of colorectal cancer. Hum. Cell 2013, 26, 162–169.
76. Baba, T.; Kawaguchi, M.; Fukushima, T.; Sato, Y.; Orikawa, H.; Yorita, K.; Tanaka, H.; Lin, C.-Y.; Sakoda, S.; Kataoka, H.; et al. Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells’ invasiveness. J. Pathol. 2012, 228, 181–192.
77. Cheng, H.; Fukushima, T.; Takahashi, N.; Tanaka, H.; Kataoka, H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res. 2009, 69, 1828–1835.
78. Fukushima, T.; Kawaguchi, M.; Yamasaki, M.; Tanaka, H.; Yorita, K.; Kataoka, H. Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. Cancer Sci. 2011, 102, 407–413.
79. Ye, J.; Kawaguchi, M.; Haruyama, Y.; Kanemaru, A.; Fukushima, T.; Yamamoto, K.; Lin, C.-Y.; Kataoka, H. Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model. Cancer Sci. 2014, 105, 44–51.
80. Tomioka, D.; Maehara, N.; Kuba, K.; Mizumoto, K.; Tanaka, M.; Matsumoto, K.; Nakamura, T. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 2001, 61, 7518–7524.
81. Kohama, K.; Kawaguchi, M.; Fukushima, T.; Lin, C.-Y.; Kataoka, H. Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells. Hum. Cell 2012, 25, 100–110.
82. Parr, C.; Jiang, W.G. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int. J. Cancer 2006, 119, 1176–1183.
83. Nagaike, K.; Kohama, K.; Uchiyama, S.; Tanaka, H.; Chijiiwa, K.; Itoh, H.; Kataoka, H. Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. Cancer Sci. 2004, 95, 728–735.
84. Komaki, W.; Fukushima, T.; Tanaka, H.; Itoh, H.; Chosa, E.; Kataoka, H. Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses. Virchows Arch. 2008, 453, 347–357.
85. Kataoka, H.; Uchino, H.; Denda, K.; Kitamura, N.; Itoh, H.; Tsubouchi, H.; Nabeshima, K.; Koono, M. Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa. Cancer Lett. 1998, 128, 219–227.
86. Domoto, T.; Takino, T.; Guo, L.; Sato, H. Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase. Cancer Sci. 2012, 103, 448–454.
87. Sato, H.; Takino, T. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci. 2010, 101, 843–847.
88. Hamasuna, R.; Kataoka, H.; Meng, J.Y.; Itoh, H.; Moriyama, T.; Wakisaka, S.; Koono, M. Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: Implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int. J. Cancer 2001, 93, 339–345.
89. Kongkham, P.N.; Northcott, P.A.; Ra, Y.S.; Nakahara, Y.; Mainprize, T.G.; Croul, S.E.; Smith, C.A.; Taylor, M.D.; Rutka, J.T. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res. 2008, 68, 9945–9953.
90. Betsunoh, H.; Mukai, S.; Akiyama, Y.; Fukushima, T.; Minamiguchi, N.; Hasui, Y.; Osada, Y.; Kataoka, H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 2007, 98, 491–498.
91. Morris, M.R.; Gentle, D.; Abdulrahman, M.; Maina, E.N.; Gupta, K.; Banks, R.E.; Wiesener, M.S.; Kishida, T.; Yao, M.; Teh, B.; et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 2005, 65, 4598–4606.
92. Morris, M.R.; Gentle, D.; Abdulrahman, M.; Clarke, N.; Brown, M.; Kishida, T.; Yao, M.; Teh, B.T.; Latif, F.; Maher, E.R.; et al. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br. J. Cancer 2008, 98, 496–501.
93. Fukai, K.; Yokosuka, O.; Chiba, T.; Hirasawa, Y.; Tada, M.; Imazeki, F.; Kataoka, H.; Saisho, H. Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res. 2003, 63, 8674–8679.
94. Dong, W.; Chen, X.; Xie, J.; Sun, P.; Wu, Y. Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer. Int. J. Cancer 2010, 127, 1526–1534.
95. Yue, D.; Fan, Q.; Chen, X.; Li, F.; Wang, L.; Huang, L.; Dong, W.; Chen, X.; Zhang, Z.; Liu, J.; et al. Epigenetic inactivation of SPINT2 is associated with tumor suppressive function in esophageal squamous cell carcinoma. Exp. Cell Res. 2014, 322, 149–158.
96. Bergum, C.; List, K. Loss of the matriptase inhibitor HAI-2 during prostate cancer progression. Prostate 2010, 70, 1422–1428.
97. Hurst, N.J.; Najy, A.J.; Ustach, C.V.; Movilla, L.; Kim, H.-R.C. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: Implications for breast cancer progression. Biochem. J. 2012, 441, 909–918.
98. Ustach, C.V.; Huang, W.; Conley-LaComb, M.K.; Lin, C.-Y.; Che, M.; Abrams, J.; Kim, H.-R.C. A novel signaling axis of matriptase/PDGF-D/β-PDGFR in human prostate cancer. Cancer Res. 2010, 70, 9631–9640.
99. Li, W.; Wang, B.-E.; Moran, P.; Lipari, T.; Ganesan, R.; Corpuz, R.; Ludlam, M.J.C.; Gogineni, A.; Koeppen, H.; Bunting, S.; et al. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis. Cancer Res. 2009, 69, 8395–8402.
100. Galkin, A.V.; Mullen, L.; Fox, W.D.; Brown, J.; Duncan, D.; Moreno, O.; Madison, E.L.; Agus, D.B. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004, 61, 228–235.
101. Gray, K.; Elghadban, S.; Thongyoo, P.; Owen, K.A.; Szabo, R.; Bugge, T.H.; Tate, E.W.; Leatherbarrow, R.J.; Ellis, V. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II. Thromb. Haemost. 2014, 112, 1–10.